Description: Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing clinical human therapeutics in Australia. It is developing Plexaris, an exosome derived from human platelets; and Exomeres, an exosome derived from adult stem cells. The company was founded in 2003 and is headquartered in Melbourne, Australia. The Company’s LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells.
Home Page: www.exopharm.com
EX1 Technical Analysis
31 Queen Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9111 0026
Officers
| Name | Title |
|---|---|
| Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D. | Founder, Technology Co-Founder, CEO MD & Director |
| Dr. Michael L. West Ph.D. | Chief Technology Officer |
| Mr. David Oxley | Pres of International |
| Dr. Gregor Lichtfuss M.Sc. | Co-Founder & Bus. Services Mang. |
| Mr. Johannes Muhl | Sr. VP of Fin. |
| Caitlin Gladman | VP of Communications |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3744 |
| Price-to-Sales TTM: | 2.5414 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 50 |